Literature DB >> 28317142

Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer.

Folefac Aminkeng1,2, Colin J D Ross3, Shahrad R Rassekh2,4, Michael J Rieder5, Amit P Bhavsar3, Shubhayan Sanatani2, Daniel Bernstein6, Michael R Hayden1,2,7, Ursula Amstutz8, Bruce C Carleton2,9.   

Abstract

Entities:  

Keywords:  anthracycline; anthracycline-induced cardiotoxicity; cancer; chemotherapy; clinical practice guidelines; congestive heart failure; pharmacogenomic screening

Mesh：

Substances：

Year:  2017        PMID： 28317142      PMCID： PMC5401971          DOI： 10.1111/bcp.13218

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  18 in total

1.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

2.  UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S).

Authors:  Soundararajan Krishnaswamy; Qin Hao; Abdul Al-Rohaimi; Leah M Hesse; Lisa L von Moltke; David J Greenblatt; Michael H Court
Journal:  J Pharmacol Exp Ther       Date:  2005-03-10       Impact factor: 4.030

3.  Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite.

Authors:  G Minotti; S Licata; A Saponiero; P Menna; A M Calafiore; G Di Giammarco; G Liberi; F Animati; A Cipollone; S Manzini; C A Maggi
Journal:  Chem Res Toxicol       Date:  2000-12       Impact factor: 3.739

Review 4.  Contribution of specific transport systems to anthracycline transport in tumor and normal cells.

Authors:  K Nagasawa; K Nagai; N Ohnishi; T Yokoyama; S Fujimoto
Journal:  Curr Drug Metab       Date:  2001-12       Impact factor: 3.731

Review 5.  Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.

Authors:  Folefac Aminkeng; Colin J D Ross; Shahrad R Rassekh; Soomi Hwang; Michael J Rieder; Amit P Bhavsar; Anne Smith; Shubhayan Sanatani; Karen A Gelmon; Daniel Bernstein; Michael R Hayden; Ursula Amstutz; Bruce C Carleton
Journal:  Br J Clin Pharmacol       Date:  2016-06-30       Impact factor: 4.335

6.  Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.

Authors:  Giuseppe Sacco; Rossella Giampietro; Emanuela Salvatorelli; Pierantonio Menna; Nicoletta Bertani; Gallia Graiani; Fabio Animati; Cristina Goso; Carlo A Maggi; Stefano Manzini; Giorgio Minotti
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

7.  Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells.

Authors:  Swati Nagar; Jeffrey J Zalatoris; Rebecca L Blanchard
Journal:  Pharmacogenetics       Date:  2004-08

8.  Common regulatory variation impacts gene expression in a cell type-dependent manner.

Authors:  Antigone S Dimas; Samuel Deutsch; Barbara E Stranger; Stephen B Montgomery; Christelle Borel; Homa Attar-Cohen; Catherine Ingle; Claude Beazley; Maria Gutierrez Arcelus; Magdalena Sekowska; Marilyne Gagnebin; James Nisbett; Panos Deloukas; Emmanouil T Dermitzakis; Stylianos E Antonarakis
Journal:  Science       Date:  2009-07-30       Impact factor: 47.728

9.  A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.

Authors:  Folefac Aminkeng; Amit P Bhavsar; Henk Visscher; Shahrad R Rassekh; Yuling Li; Jong W Lee; Liam R Brunham; Huib N Caron; Elvira C van Dalen; Leontien C Kremer; Helena J van der Pal; Ursula Amstutz; Michael J Rieder; Daniel Bernstein; Bruce C Carleton; Michael R Hayden; Colin J D Ross
Journal:  Nat Genet       Date:  2015-08-03       Impact factor: 38.330

10.  Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes.

Authors:  Agnes Maillet; Kim Tan; Xiaoran Chai; Singh N Sadananda; Ashish Mehta; Jolene Ooi; Michael R Hayden; Mahmoud A Pouladi; Sujoy Ghosh; Winston Shim; Liam R Brunham
Journal:  Sci Rep       Date:  2016-05-04       Impact factor: 4.379
View more
  3 in total

1.  Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer.

Authors:  Folefac Aminkeng; Colin J D Ross; Shahrad R Rassekh; Michael J Rieder; Amit P Bhavsar; Shubhayan Sanatani; Daniel Bernstein; Michael R Hayden; Ursula Amstutz; Bruce C Carleton
Journal:  Br J Clin Pharmacol       Date:  2017-03-19       Impact factor: 4.335

2.  RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy.

Authors:  Tarek Magdy; Zhengxin Jiang; Mariam Jouni; Hananeh Fonoudi; Davi Lyra-Leite; Gwanghyun Jung; Marisol Romero-Tejeda; Hui-Hsuan Kuo; K Ashley Fetterman; Mennat Gharib; Brian T Burmeister; Mingming Zhao; Yadav Sapkota; Colin J Ross; Bruce C Carleton; Daniel Bernstein; Paul W Burridge
Journal:  Cell Stem Cell       Date:  2021-09-15       Impact factor: 24.633

3.  Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity.

Authors:  Tarek Magdy; Mariam Jouni; Hui-Hsuan Kuo; Carly J Weddle; Davi Lyra-Leite; Hananeh Fonoudi; Marisol Romero-Tejeda; Mennat Gharib; Hoor Javed; Giovanni Fajardo; Colin J D Ross; Bruce C Carleton; Daniel Bernstein; Paul W Burridge
Journal:  Circulation       Date:  2021-12-07       Impact factor: 39.918
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.